Journal article
Emerging roles for the IL-6 family of cytokines in pancreatic cancer
Gemma van Duijneveldt, Michael DW Griffin, Tracy L Putoczki
Clinical Science | PORTLAND PRESS LTD | Published : 2020
DOI: 10.1042/CS20191211
Abstract
Pancreatic cancer has one of the poorest prognoses of all malignancies, with little improvement in clinical outcome over the past 40 years. Pancreatic ductal adenocarcinoma is responsible for the vast majority of pancreatic cancer cases, and is characterised by the presence of a dense stroma that impacts therapeutic efficacy and drives pro-tumorigenic programs. More specifically, the inflammatory nature of the tumour microenvironment is thought to underlie the loss of anti-tumour immunity and development of resistance to current treatments. Inflammatory pathways are largely mediated by the expression of, and signalling through, cytokines, chemokines, and other cellular messengers. In recent ..
View full abstractGrants
Awarded by National Health & Medical Research Council of Australia
Awarded by Australian Research Council Future Fellowship
Awarded by Victorian Cancer Agency Fellowship
Funding Acknowledgements
This work was supported by the National Health & Medical Research Council of Australia [grant number APP1098643]. M.D.W.G was the recipient of an Australian Research Council Future Fellowship (project number FT140100544). T.L.P was the recipient of a Victorian Cancer Agency Fellowship [grant number MCRF16009]; and a WEHI Dyson Bequest centenary Fellowship. Funding from the Victorian Government Operational Infrastructure Support Scheme is acknowledged.